Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Decreases By 84.3%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the target of a large drop in short interest in June. As of June 30th, there was short interest totaling 1,751 shares, a drop of 84.3% from the June 15th total of 11,177 shares. Based on an average trading volume of 10,351 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

MOLN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a research report on Monday, March 16th. Finally, HC Wainwright restated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Stock Down 2.4%

Shares of MOLN stock traded down $0.10 during trading hours on Monday, reaching $3.92. 1,363 shares of the company’s stock were exchanged, compared to its average volume of 10,246. Molecular Partners has a fifty-two week low of $3.41 and a fifty-two week high of $5.36. The stock has a market capitalization of $158.49 million, a P/E ratio of -2.02 and a beta of 1.08. The business has a fifty day moving average price of $3.97 and a 200-day moving average price of $4.26.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). As a group, research analysts expect that Molecular Partners will post -1.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.